Trials / Recruiting
RecruitingNCT04642352
Office-Based Superior Laryngeal Nerve Block for Treatment of Neurogenic Cough
Office-Based Superior Laryngeal Nerve (SLN) Block for Treatment of Neurogenic Cough
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (estimated)
- Sponsor
- University of Alabama at Birmingham · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate if office-based injection of a local anesthetic/steroid combination at the area of one superior laryngeal nerve can decrease cough frequency and alleviate symptoms of chronic cough in patients with neurogenic cough.
Detailed description
Neurogenic cough is a chronic cough without a clear cause. It is thought to be related to irritation of a nerve that goes to the larynx (voice box). This can happen after a viral upper respiratory infection. Current treatment uses therapy or medications taken by mouth. Those medications can be sedating and not well tolerated. An alternative approach would be to perform an injection "nerve block", which is commonly done for other nerve disorders such as around the spine. This may help people with neurogenic cough also. We studied this recently in a small group of patients and found that patients had improvement in their cough symptoms (Simpson 2018). It would be helpful to study this in a larger group of patients using more methods of evaluating cough symptom severity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | superior laryngeal nerve block | A unilateral injection of 2 cc of a 1:1 mixture of 0.25% bupivacaine and Kenalog-40 via a 27 gauge needle to the thyrohyoid space (front of neck, just above larynx/voice box) via a 27 gauge needle to the thyrohyoid space (front of neck, just above larynx/voice box) on the side which exhibited most discomfort/tenderness/cough on palpation. If neither side was uncomfortable, the right side will be used. |
Timeline
- Start date
- 2022-01-03
- Primary completion
- 2026-10-01
- Completion
- 2026-10-01
- First posted
- 2020-11-24
- Last updated
- 2025-02-25
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04642352. Inclusion in this directory is not an endorsement.